Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 3, 2012, Pages

  Michalski, Jeff ^a,j   Winter, Kathryn ^b   Roach, MacK ^c   Markoe, Arnold ^d   Sandler, Howard M ^e,f   Ryu, Janice ^g,h   Parliament, Matthew ⁱ   Purdy, James A ^g,j   Valicenti, Richard K ^g,k   Cox, James D ^l  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Radiation Oncology Associates   (United States)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j Image guided Therapy Center   (United States)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

^l UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

3D radiation; Conformal radiation; Dose escalation; Prostate cancer; PSA outcomes

Indexed keywords

3D CONFORMAL RADIATION THERAPY; BIOCHEMICAL FAILURE; CANCER CONTROL; CLINICAL OUTCOME; DISEASE FREE SURVIVAL; DOSE ESCALATION; DOSE LEVELS; DOSE-ESCALATION STUDY; LOCALIZED PROSTATE CANCER; NEOADJUVANT HORMONE THERAPY; OVERALL SURVIVAL; PHASE I; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; PSA OUTCOMES; RADIATION ONCOLOGY; RADIATION THERAPY ONCOLOGY GROUPS; THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY;

DISEASES; ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY; SOCIETIES AND INSTITUTIONS; UROLOGY;

THREE DIMENSIONAL;

ANDROGEN RECEPTOR ANTAGONIST; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION RESPONSE; SURVIVAL RATE; SURVIVAL TIME; THREE DIMENSIONAL CONFORMAL RADIOTHERAPY; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84861645451     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.12.070     Document Type: Article

References (25)

1. J.M. Michalski, J.A. Purdy, and K. Winter Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406 Int J Radiat Oncol Biol Phys 46 2000 391 402
2. J.M. Michalski, K. Winter, and J.A. Purdy Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V Int J Radiat Oncol Biol Phys 62 2005 706 713
3. J.M. Michalski, K. Winter, and J.A. Purdy Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV Int J Radiat Oncol Biol Phys 58 2004 735 742
4. J.K. Ryu, K. Winter, and J.M. Michalski Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy) Int J Radiat Oncol Biol Phys 54 2002 1036 1046
5. M. Roach 3rd The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 1923 1924
6. ICRU Report 50 Prescribing, recording, and reporting photon beam therapy 1993 International Commission on Radiation Units and Measurements Bethesda, MD
7. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel Int J Radiat Oncol Biol Phys 37 1997 1035 1041
8. L. Kestin, N. Goldstein, and F. Vicini Treatment of prostate cancer with radiotherapy: Should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54 2002 686 697
9. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
10. H. Thames, D. Kuban, and L. Levy Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995 Int J Radiat Oncol Biol Phys 57 2003 929 943
11. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
12. J.D. Kalbfleisch, and R.L. Prentice The Statistical Analysis of Failure Time Data 1980 John Wiley & Sons New York
13. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Stat Assoc 53 1958 457 481
14. D. Khuntia, C.A. Reddy, and A. Mahadevan Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: What should we expect? Cancer 100 2004 1283 1292
15. A. Pollack, L.G. Smith, and A.C. von Eschenbach External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era Int J Radiat Oncol Biol Phys 48 2000 507 512
16. M.J. Zelefsky, Z. Fuks, and M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 2001 876 881
17. L.L. Kestin, F.A. Vicini, and A.A. Martinez Practical application of biochemical failure definitions: What to do and when to do it Int J Radiat Oncol Biol Phys 53 2002 304 315
18. T. Pickles, C. Kim-Sing, and W.J. Morris Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias Int J Radiat Oncol Biol Phys 57 2003 11 18
19. M.V. Pilepich, K. Winter, and M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
20. A.W. Partin, J. Yoo, and H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114
21. L.L. Kestin, F.A. Vicini, and A.A. Martinez Potential survival advantage with early androgen deprivation for biochemical failure after external beam radiotherapy: The importance of accurately defining biochemical disease status Int J Radiat Oncol Biol Phys 60 2004 453 462
22. A. Al-Mamgani, W.L. van Putten, and W.D. Heemsbergen Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 980 988
23. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
24. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
25. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 2010 1106 1111